BioReperia can use zebrafish to test drugs and drug candidates to select the substance with the greatest effect against a specific cancer tumor. The market for both drug development and personalized medicine is estimated to be large.
BioReperia was founded by researchers Lasse Jensen and Anna Fahlgren, both at Linköping University. The company is a member of the business incubator Lead.
For more information, visit: www.bioreperia.com
